Santa Ana
Alameda, US · 10 known investors
Find your way into Santa Ana
1,228 people in our graph share verified history with the Santa Ana team — schools, employers, funds. One of them is your warm intro.
.jpeg)
Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases. It is building a pipeline of first-in-class and best-in-class biologics for conditions such as inflammatory bowel disease and scleroderma-associated interstitial lung disease.
Also known as Santa Ana Bio · Santa Ana Bio, Inc.
Founders & leadership
Board
Investors · 10
Also in the syndicate · 4
Company profile
researched Aug 2026Santa Ana Bio, Inc. is a precision immunology biotechnology company headquartered in Alameda, California, that develops targeted biologic therapies for autoimmune and inflammatory diseases. Rather than targeting cytokines broadly, the company seeks to identify targets expressed specifically on disease-causing cell types, aiming to address patient heterogeneity, durability of response and safety limitations it associates with existing biologic treatments.
The pipeline consists of engineered antibodies at preclinical and IND-enabling stages. SAB01 is a first-in-class bispecific antibody targeting KIT and Siglec-6, receptors co-expressed on mast cells, designed to selectively deplete mast cells for indications including chronic urticaria, prurigo nodularis, atopic dermatitis and food allergy; the company has cited a mid-2026 IND submission and Phase 1 start. SAB05 is a CD40-targeted glucocorticoid antibody-drug conjugate intended to deliver a potent steroid payload to inflamed tissue while combining clinically validated CD40 blockade, with IND submission targeted for the first half of 2027. SAB06 is a portfolio of mono-, bi- and tri-specific antibodies against TL1A, IL-23p19, TNF-alpha and related pathways for inflammatory bowel disease, Crohn's disease and scleroderma-associated interstitial lung disease, with IND submission targeted for the second half of 2027. SAB03, an anti-PD-1 monoclonal antibody intended to suppress and deplete autoreactive T cells across multiple autoimmune indications, was described in November 2025 as ready to enter IND-enabling studies.
Founding story
Versant Ventures was the founding investor, and its managing director Jerel Davis served as founding chairman. Peter Emtage, founder and CEO and a venture partner at Versant, previously served as global head of cell therapy research at Kite Pharma, chief scientific officer at Cell Design Labs and vice president of immune-mediated therapy at MedImmune.
Business model
Preclinical-stage therapeutics developer financed by venture capital, advancing proprietary antibody programs toward IND submission and clinical trials, with stated optionality to advance programs internally or pursue partnerships.
Traction
All disclosed programs remain preclinical, supported by preclinical efficacy and safety data; the earliest program, SAB01, is guided to IND submission and Phase 1 initiation in mid-2026, followed by SAB05 in the first half of 2027 and SAB06 in the second half of 2027.
Latest developments
In November 2025 the company announced the appointment of Mike Bonney, previously CEO of Cubist Pharmaceuticals, as Chair of the Board, and outlined near-term milestones including a mid-2026 Phase 1 start for SAB01, IND studies for SAB05, and development candidate progress for SAB03 and SAB06.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positions its cell- and pathway-targeted antibodies against the prevailing class of cytokine-directed biologics for autoimmune disease, which it characterizes as targeting messengers rather than causal agents and as not discriminating diseased from healthy tissue.
Emphasizes target selection restricted to disease-driving cells, such as the KIT/Siglec-6 combination said to be co-expressed only on mast cells, and site-restricted payload delivery via CD40-targeted glucocorticoid conjugation, both intended to avoid toxicities associated with broader KIT inhibition and systemic steroid use.
Technology
A precision multi-omics platform integrating genomic, transcriptomic and proteomic data to characterize disease-specific cell subpopulations and identify targets restricted to pathogenic cell types, paired with protein engineering capabilities spanning monoclonal antibodies, bispecific and multi-specific antibodies, and antibody-drug conjugates including glucocorticoid ADCs.
Go-to-market
Patients with autoimmune, allergic and inflammatory conditions including chronic urticaria, prurigo nodularis, atopic dermatitis, food allergy, inflammatory bowel disease, Crohn's disease and scleroderma-associated interstitial lung disease.
Geography
Headquartered in Alameda, California, United States.
History
The company operated in stealth before emerging publicly in June 2024 with $168 million in combined Series A and Series B financing and multiple biologics tracking toward clinical entry. In November 2025 it appointed Mike Bonney as Chair of the Board, with founding chairman Jerel Davis of Versant Ventures remaining a director, and reported that SAB01 was positioned to begin Phase 1 in mid-2026 while SAB05 advanced through IND studies and SAB03 and SAB06 approached development candidate status.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Santa Ana went on to found or lead other companies.
Timeline · 2
launches, deals, and filingsSanta Ana Bio named Mike Bonney, former CEO of Cubist Pharmaceuticals, as Chair of its Board of Directors. Jerel Davis of Versant Ventures, the founding Chairman, remains a director.
The company launched publicly with $168 million in combined Series A and Series B funding. The Series A was led by founding investor Versant Ventures with TPG's Life Science Innovations fund and GV; the $125 million Series B was led by GV with participation from existing investors plus Access Biotechnology, a16z Bio + Health and RTW.
$168M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
Santa Ana, Costa Mesa Orange and San Clemente move to raise taxes and fees: What voters need to know - New Santa Ananewsantaana.com · Sep 2026
Rep. Correa Presents Santa Ana College with $850K Workforce Training Funding - MyNewsLA.commynewsla.com · Aug 2026▸Research sources · 8
primary sources listed
- Santa Anasantaana.bio · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Santa Ana do?
- Precision immunology biotech developing engineered antibodies against autoimmune and inflammatory diseases.
- Who founded Santa Ana?
- Santa Ana was founded by Peter Emtage, Alexander Rudensky, Richard Flavell, Graham Lord, Ansuman Satpathy.
- Who are Santa Ana's investors?
- Santa Ana's investors include Versant Ventures, Access Biotechnology, Andreessen Horowitz, GV (Google Ventures), RTW Investments L.P., TPG.
- Where is Santa Ana headquartered?
- Santa Ana is headquartered in Alameda, US.